ROIV
Roivant Sciences LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$21.55B
P/E Ratio
—
EPS
$-0.54
Beta
1.14
52W High
$32.79
52W Low
$10.59
50-Day MA
$28.45
200-Day MA
$21.96
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Roivant Sciences Ltd
Roivant Sciences Ltd (ROIV) is a pioneering biopharmaceutical company focused on transforming drug development and commercialization with its innovative business model and cutting-edge technologies. With a diverse pipeline addressing substantial unmet medical needs in areas such as neurology, immunology, and rare diseases, Roivant aims to streamline the drug development process and reduce costs significantly. The company's seasoned leadership and strategic partnerships enhance its ability to navigate the complex healthcare landscape, making it an attractive prospect for institutional investors seeking opportunities that drive both financial returns and improved patient outcomes.
Fundamentals
| Revenue (TTM) | $8.26M |
| Gross Profit (TTM) | $-673.94M |
| EBITDA | $-1.28B |
| Operating Margin | -14675.00% |
| Return on Equity | -7.59% |
| Return on Assets | -14.30% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $6.02 |
| Price-to-Book | 4.76 |
| Price-to-Sales (TTM) | 2608.88 |
| EV/Revenue | 2101.42 |
| EV/EBITDA | 0.74 |
| Quarterly Earnings Growth (YoY) | -96.10% |
| Quarterly Revenue Growth (YoY) | -66.70% |
| Shares Outstanding | $719.27M |
| Float | $545.56M |
| % Insiders | 23.40% |
| % Institutions | 75.83% |
Historical Volatility
HV 10-Day
81.41%
HV 20-Day
59.71%
HV 30-Day
52.00%
HV 60-Day
44.18%
HV Rank
88.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($38.12 target)
2
Strong Buy10
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026